| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
PYR14-TFSI does not have a defined biological drug target as it is an ionic liquid used primarily as an electrolyte solvent and chemical reagent rather than a therapeutic agent. The compound's applications are in electrochemistry, energy storage, and materials science rather than in biological systems. In biomedical research, ionic liquids are studied for their potential as drug delivery vehicles, antimicrobial agents, and solvents for biocatalysis. The compound's hydrophobic nature and ionic character make it useful for studying ion transport and electrochemical properties.
|
|---|---|
| ln Vitro |
As an ionic liquid and chemical reagent, PYR14-TFSI is not typically evaluated for direct in vitro biological activity against specific molecular targets. The compound's primary applications are in electrochemistry and materials science as an electrolyte solvent. In biological contexts, ionic liquids may show antimicrobial activity or effects on cell membranes due to their ionic nature, but such effects are incidental to their primary use. The compound's biological activity in assays would depend on the specific context and concentration.
|
| ln Vivo |
In vivo activity data for PYR14-TFSI is limited, as the compound is primarily used in electrochemistry and materials science rather than as a therapeutic agent. Ionic liquids are being studied for potential biomedical applications including drug delivery, but comprehensive in vivo studies have not been extensively reported. The compound's primary applications remain in energy storage devices (batteries, supercapacitors) and as electrolytes in electrochemical systems.
|
| Enzyme Assay |
Cell-free biochemical assays involving PYR14-TFSI typically focus on its use as an electrolyte or solvent rather than as an enzyme inhibitor. In electrochemical applications, a standard protocol involves dissolving the ionic liquid in an appropriate solvent (e.g., acetonitrile or other organic solvents) and using it as an electrolyte for cyclic voltammetry, impedance spectroscopy, or battery testing. The compound's purity (≥98%) is verified by HPLC or NMR. Its high ionic conductivity and wide electrochemical window make it suitable for advanced energy storage applications.
|
| Cell Assay |
Cell-based assays are not typically performed with PYR14-TFSI as the compound is an ionic liquid used in electrochemistry and materials science rather than a drug candidate. If studying the biocompatibility of ionic liquids, standard cell-based protocols may be used to assess cytotoxicity. Cells are cultured in appropriate media, treated with varying concentrations of the ionic liquid (0.01-10 mM) for 24-72 hours, and cell viability is assessed by MTT or other assays. The compound's hydrophobic nature may affect its interaction with cell membranes.
|
| Animal Protocol |
In vivo studies are not typically conducted with PYR14-TFSI as the compound is used in electrochemistry and materials science rather than as a therapeutic agent. If evaluating the safety or biocompatibility of ionic liquids for biomedical applications, standard toxicology studies in rodents may be performed. A typical protocol includes oral or intraperitoneal administration of the compound, with monitoring of clinical signs, body weight, and tissue histopathology. However, comprehensive in vivo studies are limited.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for PYR14-TFSI is not applicable, as the compound is an ionic liquid used in electrochemistry rather than a drug. The molecular weight is 422.41 g/mol. The compound is hydrophobic and would be expected to have low aqueous solubility. For potential biomedical applications, PK studies would be required. The compound is typically handled as a liquid at room temperature.
|
| Toxicity/Toxicokinetics |
Toxicological data specific to PYR14-TFSI is limited. As with all ionic liquids and chemical reagents, standard laboratory safety precautions should be observed when handling this compound. The compound's hydrophobic nature may affect its interactions with biological systems. For potential biomedical applications, comprehensive toxicological evaluation would be required. The compound's safety profile in the context of electrochemical applications is established through standard industrial hygiene practices.
|
| References | |
| Additional Infomation |
Structure in the first source
PYR14-TFSI is a research chemical and ionic liquid rather than a pharmaceutical agent. No clinical trials or regulatory approvals exist for therapeutic use of this compound. It is commercially available from various chemical suppliers for research and industrial purposes only. The compound's primary value lies in its utility as a high-purity, room-temperature ionic liquid electrolyte solvent and safety additive for advanced electrochemical applications including batteries and supercapacitors. It is also used as a biochemical reagent for biomedical research. The compound's hydrophobic nature and high stability make it suitable for demanding electrochemical applications. |
| Molecular Formula |
C11H20F6N2O4S2
|
|---|---|
| Molecular Weight |
422.40
|
| Exact Mass |
422.076
|
| CAS # |
223437-11-4
|
| PubChem CID |
11048104
|
| Appearance |
Light yellow to yellow liquid（Density：1.4 g/cm3）
|
| Density |
1.40
|
| Boiling Point |
190.5ºC at 760mmHg
|
| Flash Point |
69ºC
|
| Vapour Pressure |
0.54mmHg at 25°C
|
| Index of Refraction |
1.4216
|
| LogP |
5.206
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
467
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C(F)(F)F)([N-]S(C(F)(F)F)(=O)=O)(=O)=O.[N+]1(C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]
|
| InChi Key |
HSLXOARVFIWOQF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H20N.C2F6NO4S2/c1-3-4-7-10(2)8-5-6-9-10;3-1(4,5)14(10,11)9-15(12,13)2(6,7)8/h3-9H2,1-2H3;/q+1;-1
|
| Chemical Name |
bis(trifluoromethylsulfonyl)azanide;1-butyl-1-methylpyrrolidin-1-ium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3674 mL | 11.8371 mL | 23.6742 mL | |
| 5 mM | 0.4735 mL | 2.3674 mL | 4.7348 mL | |
| 10 mM | 0.2367 mL | 1.1837 mL | 2.3674 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
